# Special Drug Use-results Surveillance of Scemblix Tablets

> **NCT05421091** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 550 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **OTHER:** Asciminib

## Key facts

- **NCT ID:** NCT05421091
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-04
- **Primary completion:** 2024-02-29
- **Final completion:** 2024-02-29
- **Target enrollment:** 550 (ACTUAL)
- **Last updated:** 2024-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05421091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05421091, "Special Drug Use-results Surveillance of Scemblix Tablets". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05421091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*